PMID- 26359998
OWN - NLM
STAT- MEDLINE
DCOM- 20151228
LR  - 20181202
IS  - 1524-4725 (Electronic)
IS  - 1076-0512 (Linking)
VI  - 41
IP  - 10
DP  - 2015 Oct
TI  - A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of a 
      High-Potency Topical Corticosteroid After Sclerotherapy for Reticular and 
      Telangiectatic Veins of the Lower Extremities.
PG  - 1158-63
LID - 10.1097/DSS.0000000000000467 [doi]
AB  - BACKGROUND: Although typically mild, transient, and expected, most adverse events 
      (AEs) postsclerotherapy are inflammatory in nature. OBJECTIVE: To evaluate the 
      effects of a high-potency topical corticosteroid (TC) applied immediately 
      postsclerotherapy. MATERIALS AND METHODS: Subjects undergoing bilateral lower 
      extremity sclerotherapy with polidocanol had extremities randomized to a single 
      application of betamethasone dipropionate and placebo saline solutions 
      immediately post-treatment in a double-blind manner. Adverse events were assessed 
      for each extremity by subjects at t = 0 (preapplication) and t = 15 (15 minutes 
      postapplication) and by an investigator at t = 0 and t = 15, and at Days 14 and 
      60. Subjects and investigator evaluated efficacy with a quartile improvement 
      scale. RESULTS: Sixteen female subjects completed the study. Subjects reported no 
      statistically significant differences in AEs between TC and placebo at either t = 
      0 or t = 15. Investigator scores for erythema and swelling/urtication were not 
      significantly different between groups at the same time points. Although most 
      subjects demonstrated 26% to 75% improvement at Day 60, results were not 
      significantly different between extremities on subject and investigator 
      evaluation. CONCLUSION: High-potency TC application immediately postsclerotherapy 
      produced no statistically significant differences in subject- and 
      investigator-assessed AEs and clearance rates compared with placebo. Foam 
      sclerotherapy with polidocanol is safe and effective for the treatment of lower 
      extremity reticular veins.
FAU - Friedmann, Daniel P
AU  - Friedmann DP
AD  - *Westlake Dermatology Clinical Research Center, Westlake Dermatology & Cosmetic 
      Surgery, Austin, Texas; daggerCosmetic Laser Dermatology, San Diego, California; 
      double daggerDepartment of Dermatology, University of California, San Diego, San Diego, 
      California;  section signDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, 
      Mahidol University, Bangkok, Thailand.
FAU - Liolios, Ana M
AU  - Liolios AM
FAU - Wu, Douglas C
AU  - Wu DC
FAU - Goldman, Mitchel P
AU  - Goldman MP
FAU - Eimpunth, Sasima
AU  - Eimpunth S
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Dermatol Surg
JT  - Dermatologic surgery : official publication for American Society for Dermatologic 
      Surgery [et al.]
JID - 9504371
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Sclerosing Solutions)
RN  - 0AWH8BFG9A (Polidocanol)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 826Y60901U (betamethasone-17,21-dipropionate)
RN  - 9842X06Q6M (Betamethasone)
SB  - IM
MH  - Administration, Topical
MH  - Adult
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Betamethasone/*analogs & derivatives/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - *Lower Extremity
MH  - Middle Aged
MH  - Polidocanol
MH  - Polyethylene Glycols/therapeutic use
MH  - *Postoperative Care
MH  - Prospective Studies
MH  - Sclerosing Solutions/therapeutic use
MH  - *Sclerotherapy
MH  - Telangiectasis/*therapy
EDAT- 2015/09/12 06:00
MHDA- 2015/12/29 06:00
CRDT- 2015/09/12 06:00
PHST- 2015/09/12 06:00 [entrez]
PHST- 2015/09/12 06:00 [pubmed]
PHST- 2015/12/29 06:00 [medline]
AID - 10.1097/DSS.0000000000000467 [doi]
PST - ppublish
SO  - Dermatol Surg. 2015 Oct;41(10):1158-63. doi: 10.1097/DSS.0000000000000467.